史密斯内修 SNN

Deepak joins Smith+Nephew from Siemens Healthineers (2018-2022) where most recently he was President of the Diagnostics business segment responsible for $6 billion of sales and 15,000 employees. During his time there he led a major programme to drive growth and margin expansion through improved execution and a strong results-focused culture. Prior to Siemens Healthineers, Deepak held a number of senior roles at Abbott Laboratories Inc (2007-2017) spanning R&D, marketing, commercial and divisional leadership, rising to become President of Abbott Vascular and an Executive Officer of Abbott Laboratories. At Abbott he significantly improved performance of the Vascular business and had a leadership role in the $28 billion acquisition of St Jude Medical. Deepak also worked for Amgen (2004-2007), McKinsey and Company (2000-2004) and as a scientist at the Lawrence Livermore National Laboratory. He holds BSc and MSc degrees in Mechanical Engineering and a PhD in Theoretical Mechanics from the University of California, Berkeley. External appointments: Non-executive director of Reckitt Benckiser Group plc

Rupert Soames, non-executive director, will be appointed as Chairman of the board with effect from 15 September 2023. Mr Soames has extensive global leadership experience in both executive and non-executive roles. Most recently he served as Chief Executive Officer of Serco Group plc, the global outsourced services provider, between 2014 and 2022 where he led the successful turnaround. He was Chief Executive of Aggreko plc, the support services company (2003-2014) and also served as a Non-Executive Independent Director at both DS Smith, the sustainable packaging business (2019-2022) and support services company Electrocomponents plc (2007-2016) (now RS Group).

Marc Owen, Senior Independent non-executive director, will remain on the board as non-executive director with effect from 01 October 2024 Marc graduated from Oxford University with a BA and BCL in Law. In 1984 he was called to the Bar, following four years at Corpus Christi College Cambridge as a fellow and director of studies in law. He decided upon a corporate career and undertook an MBA at Stanford University. Marc commenced his healthcare and technology career at McKinsey & Company where he progressed to senior partner and eventually a founding partner of McKinsey’s Business Technology Office. In 2001, Marc joined McKesson Corporation and served as Executive Vice President and member of their Executive Committee. He delivered strategic objectives and led over 40 acquisitions and divestments over a 10-year period. In late 2011 he headed McKesson Speciality Health, which operates over 130 cancer centres across the US and provides market intelligence, supply chain services, patient access to therapy, provider and patient engagement and clinical trial support. In 2014, he was appointed Chair of the European Management Board at Celesio AG. He retired in March 2017 once he had improved operations, set the strategy and recruited his successor. Other current appointments – None

John graduated from Wayne State University with an MSc and a Ph.D. in Materials Science and Engineering. In 1995, John became a Manager of International Operations at the Performed Line Products Company. After five years he joined GE Healthcare and became Vice President and General Manager of their Global Product Company in China. In 2002, John was promoted and became responsible for GE Healthcare’s commercial division across central China where he successfully led sales, marketing and customer service teams for their $200m diagnostics medical imaging business. John has also held a number of senior positions as President of Asia Pacific regions at Pentair Inc., Vice President of Express Scripts Inc., and Global Partner of Fosun Group. He initially joined Fosun Pharma to lead their medical device business and in 2014 became President of Fosun Healthcare Holdings. He served as a key member of their healthcare investment committee which went on to establish a global presence across the US, Europe, Israel and China. In 2017, John joined Intuitive Surgical as their Senior Vice President of Strategic Growth Initiatives. He has previously served as a NED for both Haier Electronics Group and Clinical Innovations LLC. Other current appointments – Founder, Chair and Chief Executive Officer of Ronovo Surgical.

Angie Risley, non-executive director, will be appointed as Senior Independent non-executive director with effect from 01 October 2024. After graduating from Exeter University, Angie joined United Biscuits followed by Pizza Hut (UK) Ltd as Human Resources Director, a joint venture between PepsiCo, Inc. and Whitbread plc. After five years she joined Whitbread plc, becoming an Executive Director responsible for HR and Corporate Social Responsibility in 2004. Between 2007–2013 she was the Group HR Director for Lloyds Banking Group, joining J Sainsbury plc as Group HR Director and a member of their Operating Board in January 2013. Over the years, Angie has been a member of the Low Pay Commission and has held a number of Non-Executive Directorships with Biffa plc, Arriva and Serco Group plc, and now Smith+Nephew. At Serco Group plc she was the Chair of the Remuneration Committee. Previously she has attended Remuneration Committees of Whitbread plc, Lloyds Banking Group, Arriva and now J Sainsbury plc. Other current appointments – J Sainsbury plc Group HR Director and member of their Operating Board.

Jez joined the Board in 2023 and has extensive financial experience across a diverse range of industries and sectors. Jez was Chief Financial Officer of 5 UK-listed companies over a period of 24 years and has served as a Non-Executive Director on boards of companies addressing strategic and operational challenges across a number of different industries, including life-sciences and healthcare. He was previously Chair of the Audit Committee at Synthomer PLC and PZ Cussons plc. Current external appointments Senior Independent Director, Travis Perkins plc. Non-Executive Director and member of the Audit Committee at Intertek Group plc. Jez retired in 2023 as Group Finance Director at Croda International plc, the FTSE 100 global speciality chemicals company, and previously held similar roles at National Express Group plc and Northern Foods Limited. He has served as the Senior Independent Director at Synthomer PLC and at both PZ Cussons plc and Synthomer PLC he chaired the Audit Committee and served on the Remuneration Committee. He is a fellow of the Chartered Institute of Management Accountants.

Sybella Stanley will be appointed to the board as Independent Non-Executive director with effect from 01 February 2025. Sybella has worked for RELX Plc since 1997 and is currently Director of Corporate Finance. She retired in December 2024 from the Board of Tate & Lyle plc where she served for nine years as an Independent Non-Executive Director and was Chair of the Remuneration Committee. She served for nine years as an Independent Non-Executive Director of Merchants Trust PLC and as Senior Independent Director and Chair of the Remuneration Committee until her retirement in March 2024. She is also co-chair of the Development Board of Somerville College, Oxford.

Simon Lowth will be appointed to the board as Independent non-executive director with effect from 01 January 2024. Simon Lowth has deep experience in finance, accounting, risk, corporate strategy as well as mergers and acquisitions. He currently serves as Group Chief Financial officer of BT Group, a role he has held since 2016 and previously performed the same role at BG Group, AstraZeneca and Scottish Power. Before joining Scottish Power, he led the Industrial Practice of McKinsey in the UK and has a background in engineering. He previously served as a Non-Executive Director on the Board of Standard Chartered. He currently holds no additional external appointments.

Jo is a Chartered Engineer with a degree in Engineering from the University of Cambridge. She also holds an MBA from INSEAD. Jo commenced her career at Procter & Gamble (P&G) and held increasingly senior positions based in Germany, the US, Thailand and the Netherlands. On completing her MBA, she joined Bosch where she held a business unit leadership role in their Power Tools division. In 2009, Jo joined Invensys plc to run their global heating controls business unit including launching its first smart home offer. She then moved to Spectris plc, where she had responsibility for a portfolio of global industrial technology businesses, as well as for the Group’s digital strategy. Since 2019, Jo has served as Chief Executive Officer for Tyman plc, the FTSE 250 international supplier of engineered components to the doors and windows industry, where she has made sustainability a core foundation of the group’s strategy. Jo was also previously Chair of the Remuneration Committee for Norcros plc. Other current appointments – Chief Executive Officer of Tyman PLC.

Katarzyna qualified as a medical doctor (Ph.D.) from the Medical University of Gdansk, Poland in 1987 and completed an Executive MBA at the University of Minnesota, US, in 2002. Katarzyna commenced her corporate career in 1998 at Roche as a Business Unit Manager prior to becoming General Manager for Poland of Allergy Therapeutics plc. In 2001, Katarzyna was recruited by Abbott Laboratories where she successfully managed their diabetes care division in Poland. Over the next nine years, her career progressed at Abbott Laboratories to Divisional Vice President for Europe. In 2010, she continued her career at Zimmer as President of their EMEA region. Following her appointment as an executive committee member prior to the Biomet acquisition, Katarzyna supported the operations of the Zimmer Biomet portfolio covering sales, marketing, logistics, and clinical support. Since 2018, Katarzyna has served as Chief Executive Officer for the €2.7 billion EMEA business of Fresenius Medical Care AG & Co. KGaA, the German-listed renal care company. Other current appointments – Chief Executive Officer, EMEA, at Fresenius Medical Care AG & Co. KGaA. – NED at Vifor Fresenius Medical Care Renal Pharma Ltd.

David King has been appointed to the board as non-executive director with effect from 01st July 2025. David is currently CEO, executive director and chair of Fortis Life Sciences. He also serves, or has recently served, as a Chair or non-executive director on the boards of several US healthcare companies including ZimVie (2022 - 2025), VaxCare (2021 - 2025), Privia Health, Health Channels, LGC and AmSurg Corporation. David served as executive chair and CEO for Laboratory Corporation of America (LabCorp) from 2007 to 2020 and prior to that was a partner at Hogan & Hartson LLP (now Hogan Lovells).

Garheng Kong will be appointed to the board as independent non-executive director with effect from 01 September 2025. Garheng is currently managing partner and co-founder of HealthQuest Capital. He also serves as lead independent director of Laboratory Corporation of America (LabCorp) and a non-executive director of Xeris Biopharma Holdings Inc, Lunit Inc and IKS Health. Garheng was previously managing general partner of Sofinnova Investments, Inc and served as a non-executive director of Venus Concept, Inc, Alimera Sciences and Avedro, Inc and as chair of Histogenics Corporation.

Thérèse Esperdy has been appointed to the board as non-executive director with effect from 01 December 2025. Thérèse is currently non-executive chair of Imperial Brands plc and non-executive director of Moody's Corporation and was previously senior independent director of National Grid plc. In her executive career Thérèse held senior leadership roles with JP Morgan including global chair of their Financial Institutions Group, co-head of Asia-Pacific Corporate & Investment Banking and global head of Debt Capital Markets. External appointments: Non-Executive Director and Chair-designate of Rentokil Initial plc.